



**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: A8689

SINGH, Rajeeva, et al.

Appln. No.: 10/729,441

Group Art Unit: 1641

Confirmation No.: 3309

Examiner: Unassigned

Filed: December 08, 2003

For: ANTI-IGF-I RECEPTOR ANTIBODIES

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.


The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



---

Drew Hissong  
Registration No. 44,765

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: August 3, 2005

Substitute for Form 1449 A &amp; B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	10/729,441
Confirmation Number	3309
Filing Date	December 08, 2003
First Named Inventor	SINGH, Rajeeva
Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	A8689

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		2003/0165502		09/04/2003	Fujita-Yamaguchi
		2004/0086503		05/06/2004	Cohen et al.
		2003/0236190		12/25/2003	Pillutla et al.
		2004/0023887		02/05/2004	Pillutla et al.
		2004/0086503		05/06/2004	Pfizer, Inc.
		2005/0084906		04/21/2005	Pierre Fabre Medicament
		2003/0018191		01/29/2004	Schering Corp.
		2003/0099655		05/29/2003	Watkins et al.
		5,530,101		06/25/1996	Queen et al.
		6,875,741		04/05/2005	Pillutla et al.

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		WO	04/083248		09/30/04	Runnels et al.	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		Grant et al, <i>J. Clin. Endocrin. Metabol.</i> , 83:3252-3257 (1998)	
		Steele-Perkins and Roth, <i>Biochem. Biophys. Res. Comm.</i> 171(3):1244-1251 (1990)	
		Harlow and Lane, eds. Using Antibodies, A Laboratory Manual, pp. 81-97, 126-127, 166-169, Cold Spring Harbor Press 1999	
		Kato et al., <i>J. Biol. Chem.</i> 268:2655-2661 (1993)	
		Fundamental Immunology, William E. Paul, M.D. ed., 3d ed., pg. 242, 1993	
		Rudikoff et al., <i>Proc. Natl. Acad. Sci USA</i> , 79:1979-1983 (1982)	
		Zia et al., <i>J. Cellular Biochem Suppl.</i> 24:269-275 (1996)	
		Roguska et al., <i>Proc. Natl. Acad. Sci USA</i> , 91:969-973 (1994)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.